IP Library › Granted Patent US 12,414,980
Granted Patent B2
US 12,414,980 · App. 17/239,433 · Granted Sep 16, 2025

Pharmaceutical composition comprising RUNX3 protein and CDK4 inhibitor or mTOR inhibitor cotreatment for prevention or treatment of cancer

Inventors: Suk Chul Bae (Cheongju-si, KR); Jung Won Lee (Daejeon, KR); You Soub Lee (Cheongju-si, KR)
Assignee: GeneCraft, Inc.
A61K38/17A61K31/436A61K31/519A61K38/1709A61K47/46A61P35/00C07K14/4702C12N7/00C12N2750/14143
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,414,980
App. No.
17/239,433
Granted
Sep 16, 2025
Kind
B2
Abstract

The present invention relates to a pharmaceutical composition for prevention or treatment of cancer, comprising a Runx3 (Runt-related transcription factor 3) protein, a polynucleotide encoding thereof, a vector carrying the polynucleotide or a virus or cell transformed with the vector; and a CDK4 inhibitor or an mTOR inhibitor as an active ingredient. It was confirmed that the binding of Runx3 and BRD2 was maintained for up to 8 hours when the CDK4 inhibitor (PD0332991) was present at the concentration of 11 nM known to be non-toxic to normal cells. It was also confirmed that the binding of Runx3 and BRD2 was maintained for up to 8 hours when the mTOR inhibitor (rapamycin) was present at the concentration of 100 nM known to be non-cytotoxic to normal cells. In addition, it was confirmed that the cancer apoptotic effect was significantly increased when the CDK4 inhibitor or mTOR inhibitor was administered simultaneously with Runx3 than when Runx3 was administered alone to Runx3 deficient cancer cells. Therefore, the CDK4 inhibitor or mTOR inhibitor can be effectively used for preventing or treating various cancers by administering the same in combination with Runx3.

Claims (10)

1. A method for treating K-Ras mutant non-small cell lung cancer in a subject in need thereof, comprising:

administering a viral vector comprising a nucleic acid molecule encoding Runx3 (Runt-related transcription factor 3) at a therapeutically effective apoptotic amount for treating K-Ras non-small cell lung cancer, wherein the Runx3 comprises the amino acid sequence of SEQ ID NO: 11 or 12, in combination with administering a non-therapeutic, non-apoptotic amount of palbociclib at a concentration of 11 nM;

wherein the therapeutically effective apoptotic amount of Runx3 leads to apoptosis of mutant K-Ras non-small cell lung cancer cells, and wherein said apoptosis is increased by the combination of the non-therapeutic, non-apoptotic amount of palbociclib at a concentration of 11 nM.

2. A method for treating K-Ras mutant non-small cell lung cancer in a subject in need thereof, comprising:

administering a viral vector comprising a nucleic acid molecule encoding Runx3 (Runt-related transcription factor 3) at a therapeutically effective apoptotic amount for treating K-Ras non-small cell lung cancer, wherein the Runx3 comprises the amino acid sequence of SEQ ID NO: 11 or 12, in combination with administering a non-therapeutic, non-apoptotic amount of rapamycin at a concentration of 100 nM;

wherein the therapeutically effective apoptotic amount of Runx3 leads to apoptosis of mutant K-Ras non-small cell lung cancer cells, and wherein said apoptosis is increased by the combination of the non-therapeutic, non-apoptotic amount of rapamycin at a concentration of 100 nM.

3. The method for treating lung cancer according to claim 1 , wherein the viral vector is selected from a group consisting of retrovirus, adenovirus, herpes simplex virus and lentivirus.

4. The method for treating lung cancer according to claim 2 , wherein the viral vector is selected from a group consisting of retrovirus, adenovirus, herpes simplex virus and lentivirus.

5. The method for treating lung cancer according to claim 1 , wherein the viral vector is an adenovirus.

6. The method for treating lung cancer according to claim 2 , wherein the viral vector is an adenovirus.

Assignments (2)
CHANGE OF NAME Recorded Apr 20, 2023
From: RUN X CORPORATION
To: GENECRAFT INC.
Reel/Frame 063397/0450 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 17, 2021
From: BAE, SUK CHUL; LEE, JUNG WON; LEE, YOU SOUB
To: RUN-X CORPORATION
Reel/Frame 056574/0576 →
Priority Claims (2)
KR 10-2020-0049341 · Apr 23, 2020 · national
KR 10-2020-0184526 · Dec 28, 2020 · national
Continuity (1)
Related Publication 20210330742A1 · Oct 28, 2021
References Cited (30)
US 20080261883A1 · Bae et al. · 2008 [cited by applicant]
US 20120128642A1 · Teumer · 2012 [cited by examiner]
US 20150336967A1 · Czardybon · 2015 [cited by examiner]
US 20180002393A1 · Bancel et al. · 2018 [cited by applicant]
US 20210330740A1 · Bae et al. · 2021 [cited by applicant]
US 20220088126A1 · Bae et al. · 2022 [cited by applicant]
KR 1020020063387 · 2002 [cited by applicant]
KR 101994957 · 2019 [cited by applicant]
WO WO2013151672A2 · 2013 [cited by applicant]
Berns, “Cancer: The blind spot of p53,” [cited by applicant]
Feldser et al., “Stage-specific sensitivity to p53 restoration during lung cancer progression,” [cited by applicant]
Ito et al., “The RUNX family: developmental regulators in cancer,” [cited by applicant]
Junttila et al., “Selective activation of p53-mediated tumour suppression in high-grade tumours,” [cited by applicant]
Lee et al., “Runx3 is required for the differentiation of lung epithelial cells and suppression of lung cancer,” [cited by applicant]
Lee et al., “Runx3 Inactivation is a Crucial Early Event in the Development of Lung Adenocarcinoma,” [cited by applicant]
Lee et al., “RUNX3 protects against oncogenic KRAS,” [cited by applicant]
Lee et al., “RUNX3 regulates cell cycle-dependent chromatin dynamics by functioning as a pioneer factor of the restriction-point,” [cited by applicant]
“Study on the decision making mechanism for cell division,” Final (Result) Report of Research Fellow for Academic Successor Generation Project, 2017 (w/English translation of summary of research results). [cited by applicant]
Walter et al., “RB constrains lineage fidelity and multiple stages of tumour progression and metastasis,” [cited by applicant]
Wang et al., “Comparison of Adenoviral and Adeno-Associated Viral Vectors for Pancreatic Gene Delivery In Vivo,” [cited by applicant]
Wang et al., “Targeting adeno-associated virus and adenoviral gene therapy for hepatocellular carcinoma,” [cited by applicant]
El-Aneed, Anas, “An overview of current delivery systems in cancer gene therapy,” [cited by applicant]
Strausberg et al., “Generation and initial analysis of more than 15,000 full-length human and mouse cDNA sequences,” [cited by applicant]
Mukhopadhyay et al., “The Enigma of Rapamycin Dosage,” [cited by applicant]
Xue et al., “Therapeutic evaluation of palbociclib and its compatibility with other chemotherapies for primary and recurrent nasopharyngeal carcinoma,” [cited by applicant]
Zhang et al., “PTHrP prevents chondrocyte premature hypertrophy by inducing cyclin-D1-dependent Runx2 and Runx3 phosphorylation, ubiquitylation and proteasomal degradation,” [cited by applicant]
Kemp et al., “Elimination of background recombination: somatic induction of Cre by combined transcriptional regulation and hormone binding affinity,” [cited by applicant]
Kudo et al., “Oncogenic Role of RUNX3 in Head and Neck Cancer,” [cited by applicant]
Lee et al., “RUNX3 functions as an oncogene in ovarian cancer,” [cited by applicant]
Stolze et al., “Comparative analysis of KRAS codon 12, 13, 18,61, and 117 mutations using human MCFIOA isogenic cell lines,” [cited by applicant]